test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test test

• Email Address

  test

• Phone number

  fbkvbhdab

• Extension

  fhuehwfejbd

Dave joined GSK in 1992 at Worthing as a PhD Chemist from Glasgow University. He has over 20 years’ experience with the company carrying out a number of Technical, Compliance and Manufacturing leadership roles. In 1997 he moved to Irvine to take up a lead chemist role before coming Quality Control Manager in 1998. He joined the site leadership team in 2001 to run Technical Development before moving to manufacturing as Actives Production Director in 2005. During this time he completed a Masters degree in Manufacturing Leadership at Cambridge University. In 2007 he moved to GSK House to work on a central network re-structuring project before becoming Site Director at Montrose in October 2008. At Montrose, he led the transformation of the site to manufacture over 12 products for GSK including a major investment programme. In 2011 he was appointed VP Primary Supply Chain with responsibility for global Active Pharmaceutical Ingredients (API) manufacture and supply, a network of GMS sites across the world including facilities in Asia and Europe. In 2017 he was appointed VP Head of GMS Strategy with responsibility for manufacturing strategy, deployment of strategic programmes, performance management and advocacy.
He plays an active role with a number of Governments and is currently co-chair of the Life Sciences Scotland Industry Leadership Group. Dave is also a member of UK Chemicals Industry Association Board.
Dave is married with 4 children and lives in Troon, Ayrshire.

In his current position within Pall Biotech, Peter Levison is responsible for developing strategic partnerships within the Biotech community through the management of a global Key Opinion Leader network. Working with key industrialists and academics around the world, Peter is actively looking for solutions to tomorrow’s challenges today. Previously he has held a global product management leadership role for the continuous processing portfolio of products and process chromatography columns and systems. He joined Pall in July 2003 and has over 25 years experience in the biopharmaceutical industry, holding positions of increasing responsibility in research and development, technical management, and product management.

Dr. Levison holds a BSc (Hons) Class I in Biochemistry from the University of Manchester, Manchester, UK and a PhD gained in the Dept. of Biochemistry, University of Manchester. He has an MBA awarded through the Open University Business School, Milton Keynes, UK. He is a member of various professional bodies and has the status of C.Chem, FRSC (Chartered Chemist and Fellow of the Royal Society of Chemistry in the UK) and C.Biol, FRSB (Chartered Biologist and Fellow of the Royal Society of Biology in the UK).

Dr Kate Barclay is an Independent Consultant working across high impact Science and Technology industries with a passion for STEM education. As a Chartered Chemical Engineer and Fellow of the IChemE, she has spent over 20 years in the Bio-Pharmaceutical Industry as a Senior Leader in Global R&D across 3 large Pharma organisations leading technical and scientific project teams in clinical manufacture of parenteral, solid dose and inhaled dosage forms as well as developing novel device technologies.

Since 2013 Kate has been instrumental in developing apprenticeships across the Science Industry, leading the Life Sciences and Industrial Sciences Trailblazer employer group in development of new apprenticeship standards. She pioneered apprenticeship implementation across the science industry leading to the first cohort completing new standards in 2016 and has won multiple national awards for quality of apprenticeship delivery.

Kate has a passion for promoting opportunities for women in STEM, is an experienced vocational workplace assessor for apprenticeships and a Non-Executive Director of the Institute for Apprenticeships, assuring quality governance to apprenticeship and Technical Education reforms across England. Kate also volunteers as a Parent Governor and Enterprise Advisor to primary and secondary schools providing advice on career pathways and the many exciting opportunities within Science and Engineering.

Brendan is Director of New Product Introduction and Process Technology at GSK’s Barnard Castle Manufacturing Facility. He has technical accountability for introduction of all new products to site as well as managing the technical support and continuous improvement of existing products.

Brendan joined GSK in October 2009 and was previously Director of Bioprocess Sciences at MedImmune Cambridge. In this role he was responsible for all aspects of the development of purification methodologies, product characterisation, QC, potency, formulation & drug delivery for MedImmune products in relation to their use in commercial pharmaceutical processes.

Andy is the Site Manager at Macclesfield which is AstraZeneca’s second biggest manufacturing site and supplies Tablets, Sterile Devices and Parenteral and Tablet packs to around 130 markets globally. Andy is a Fellow of the Institute of Chemical Engineers and has worked for ICI, Zeneca and AstraZeneca since 1987. Andy has worked across Supply Chain Management, Major Capital and IS projects, Engineering and Manufacturing Management during his career and is currently chairman of the Medicines Manufacturing Industry Partnership.

Ray Field is Director BioPharmaceutical Development for MedImmune, the global biologics research and development arm of AstraZeneca. He is also CMC Team Leader for several clinical stage biologics projects across different therapeutic areas and leads multiple academic-industrial collaborations. He has held a number of roles since joining MedImmune (formerly Cambridge Antibody Technology, CAT) in 1994, including leading the company’s upstream and cell sciences group which has developed successful upstream processes for clinical stage biologics, including Durvalumab/Imfinzi.

Prior to joining CAT, Ray was Head of Laboratory for the biotechnology section of Zeneca Pharmaceuticals (now AstraZeneca), and before that a team leader in the process development group at Celltech Biologics (now Lonza).

Ray graduated with an honours degree in Biochemistry from the University of Warwick, and gained a PhD in Biochemistry at the University of Glasgow. Ray is an author on numerous publications on upstream processing and bioprocessing and an inventor on several patents. He also has held roles on the management committees of both BRIC and BioProNET-1/2.

In his current position within Pall Biotech, Peter Levison is responsible for developing strategic partnerships within the Biotech community through the management of a global Key Opinion Leader network. Working with key industrialists and academics around the world, Peter is actively looking for solutions to tomorrow’s challenges today. Previously he has held a global product management leadership role for the continuous processing portfolio of products and process chromatography columns and systems. He joined Pall in July 2003 and has over 25 years experience in the biopharmaceutical industry, holding positions of increasing responsibility in research and development, technical management, and product management.

Dr. Levison holds a BSc (Hons) Class I in Biochemistry from the University of Manchester, Manchester, UK and a PhD gained in the Dept. of Biochemistry, University of Manchester. He has an MBA awarded through the Open University Business School, Milton Keynes, UK. He is a member of various professional bodies and has the status of C.Chem, FRSC (Chartered Chemist and Fellow of the Royal Society of Chemistry in the UK) and C.Biol, FRSB (Chartered Biologist and Fellow of the Royal Society of Biology in the UK).

Jim has over 20 years’ experience working in the biotech and biopharmaceutical sector. He has held senior management positions at Cantab biopharmaceuticals (CEO), Xenova Biomanufacturing (Director of Operations) and Xenova Research Ltd (Leader, Upstream Process Development and Technical Business Development). Jim originally joined Cantab Pharmaceuticals, before its acquisition by Xenova, as a senior scientist in Upstream Process development and GMP Manufacturing in 1997. He has an extensive technical background in bioprocess development and GMP manufacturing, having worked on a diverse range of bioproducts from enzymes and recombinant proteins to live vaccines and conjugates. Jim’s experience ranges from products in early-stage research to those in Phase 3 clinical development. Jim has a PhD in microbial physiology and biochemistry from the University of Leicester and has published a number of papers on microbial enzymes, upstream and downstream process development.

Cobra Biologics: International the global biopharmaceutical industry.
3 facilities, 2 in Sweden and 1 in the UK, 245 employees
Orders £40m in 2017, 85% exported >50 customers
Queens Award for International Trade 2018
Bionow Company of the Year 2017
£15m Advanced Therapy Expansion Plan 2017-2019
£3m government grant awarded in 2017

Prior to his appointment as CEO in 2011, Peter was also the Cobra CFO from its IPO in 2002, through to its acquisition and subsequent separation from Recipharm. Before Cobra he was employed in a number of senior financial and corporate development roles. Peter was awarded an MBA with distinction jointly from the Manchester Business School and the University of Wales.

He is also currently the CFO of Prokarium Limited which is a biopharmaceutical company focused on developing vaccination and cancer immunotherapy solutions using synthetic biology. The company recently completed a successful $10m fund raising in Jan 2018.

Since his appointment as Chief Executive of the BioIndustry Association in 2012, Steve has led major BIA campaigns for, amongst other things, improved access to finance, the refilling of the Biomedical Catalyst, anti-microbial resistance and the opportunity the sector presents to generalist long term investors. Steve champions the adaptive pathway approach to the licensing of new drugs, the need for Early Access and is particularly proud of the working relationship the BIA has established with the UK’s leading medical research charities.

A founder member of United Life Sciences, a strategic partnership representing over 1000 life science and healthcare member companies across the UK and internationally, Steve attends the UK’s Ministerial Industry Strategy Group, and sits on The Royal Society's Science, Industry and Translation Committee.

Beyond the UK Steve is a member of EuropaBio’s Board and its National Association Council and is a founder member of the International Confederation of Biotech Associations. An expert and regular commentator on the sector in the media and at industry-leading conferences Steve has worked both in biotech (as Senior Director at Genzyme UK and Ireland) and at the highest levels of UK government (as Special Advisor to John Reid, MP, during his time in Tony Blair’s government) for over 15 years. Steve was awarded the OBE in January 2017.